专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240358681A1 METHODS OF USE OF PPAR AGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF 审中-公开
公开(公告)号：US20240358681A1
公开(公告)日：2024-10-31
申请号：US18566516
申请日：2022-06-02
申请人： Mitobridge, Inc. , Astellas Pharma, Inc.
发明人： Naotoshi Kanemitsu , Mototsugu Ito , George Mulligan , Seiji Takae , Marina Tanaka
IPC分类号： A61K31/4174 , A61K47/12 , A61K47/26 , A61K47/38 , A61P3/00
CPC分类号： A61K31/4174 , A61K47/12 , A61K47/26 , A61K47/38 , A61P3/00
摘要： The present disclosure relates to methods of use of an agonist of peroxisome proliferator-activated receptors delta (PPARδ) (e.g., Compound (I) or a pharmaceutically acceptable salt thereof disclosed herein), for example, for treating patients having primary mitochondrial myopathies (PMM). The present disclosure also relates to a pharmaceutical composition comprising an agonist of peroxisome proliferator-activated receptors delta (PPARδ) and croscarmellose sodium.

2. 发明授权

US10058536B2 Pharmaceutical composition containing mirabegron 有权
公开(公告)号：US10058536B2
公开(公告)日：2018-08-28
申请号：US15553107
申请日：2016-03-31
申请人： ASTELLAS PHARMA INC.
发明人： Seiji Takae , Toshiro Sakai , Yuki Kasashima , Yurina Ansei , Tsuyoshi Kiyota
IPC分类号： A61K9/50 , A61K31/425 , A61K31/426 , A61K31/167 , A61K47/12 , A61K9/10 , A61K47/36 , A61K47/50 , A61K47/32
CPC分类号： A61K31/426 , A61K9/10 , A61K31/167 , A61K47/12 , A61K47/32 , A61K47/36 , A61K47/50
摘要： To provide: (1) a modified release liquid (suspension) containing mirabegron, (2) a ready-to-suspend pharmaceutical composition containing mirabegron, and (3) a mirabegron-containing pharmaceutical composition that does not generate undissolved lumps, even when it is suspended at the time of use. The present invention relates to a pharmaceutical composition containing a complex of mirabegron or a pharmaceutically acceptable salt thereof with sodium polystyrene sulfonate.

3. 发明授权

US09408835B2 Pharmaceutical composition for oral administration 有权
标题翻译：用于口服给药的药物组合物
公开(公告)号：US09408835B2
公开(公告)日：2016-08-09
申请号：US14779328
申请日：2014-03-28
申请人： ASTELLAS PHARMA INC.
发明人： Seiji Takae , Hiroyuki Kojima , Atsushi Sakurai , Tetsuya Tamura , Hiroaki Tasaki , Atsushi Muro
IPC分类号： A61K31/437 , A61K9/20 , A61K9/28
CPC分类号： A61K31/437 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2095 , A61K9/2806
摘要： A pharmaceutical composition containing, as the active ingredient, 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide, of which the solubility in an acidic pH region is different from that in a neutral pH region, with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance, is provided. The pharmaceutical composition for oral administration of the present invention contains 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof, and a hydrophilic lubricant, and is useful as a pharmaceutical composition for oral administration with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance.
摘要翻译：含有作为活性成分的4 - {[（1R，2s，3S，5s，7s）-5-羟基-2-金刚烷基]氨基} -1H-吡咯并[2,3-b]吡啶-5 甲酰胺，其在酸性pH区域中的溶解度与中性pH区域的溶解度不同，具有快速的崩解性能和快速的药物溶解性以及期望良好的药物剂量依从性。本发明的口服药物组合物含有4 - {[（1R，2s，3S，5s，7s）-5-羟基-2-金刚烷基]氨基} -1H-吡咯并[2,3-b] 5-甲酰胺或其药学上可接受的盐和亲水润滑剂，并且可用作口服给药的药物组合物，其具有快速的崩解性能和快速的药物溶解性以及期望良好的药物剂量依从性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式